Global burden of heart failure attributable to hypertensive heart disease: a 30-year population-based analysis using Global Burden of Disease 2021 data.
{"title":"Global burden of heart failure attributable to hypertensive heart disease: a 30-year population-based analysis using Global Burden of Disease 2021 data.","authors":"Yun Huang, Lili Ma, Yuyu Zhang, Weibo Rong, Ronghui Zhang, Chongbo Fang, Rixiang Wang, Hua Zhou","doi":"10.1093/ajh/hpaf232","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypertensive heart disease is a major cause of heart failure (HF); this study evaluates the global burden and trends of HF attributable to hypertensive heart disease from 1990 to 2021.</p><p><strong>Methods: </strong>We collected detailed information on prevalence, years lived with disability of HF attributable to hypertensive heart disease from the Global Burden of Disease study 2021 across 204 countries and territories. Numbers, age-standardized rates, and average annual percent change of HF attributable to hypertensive heart disease prevalence and years lived with disability were compared by age, sex, and socio-demographic index.</p><p><strong>Results: </strong>In 1990 and 2021, hypertensive heart disease-related HF affected more than 4.6 million and 13 million individuals globally, demonstrating an age-standardized prevalence rate of 125.4 [95% uncertainty interval (UI), 99.0 to 158.0] and 148.3 per 100,000 (95% UI, 117.3-186.3) and an age-standardized years lived with disability rate of 11.2 (95% UI, 7.2-15.7) and 13.2 (95% UI, 8.4-19.1) per 100,000, respectively. Notably, from 1990 to 2021, the global age-standardized prevalence and years lived with disability rates increased consistently, with an average annual percent change of 0.53 (95% CI, 0.52-0.54) and 0.54 (95% CI, 0.53-0.55), respectively.</p><p><strong>Conclusions: </strong>The global burden of HF attributable to hypertensive heart disease has risen.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"704-715"},"PeriodicalIF":2.9000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajh/hpaf232","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Hypertensive heart disease is a major cause of heart failure (HF); this study evaluates the global burden and trends of HF attributable to hypertensive heart disease from 1990 to 2021.
Methods: We collected detailed information on prevalence, years lived with disability of HF attributable to hypertensive heart disease from the Global Burden of Disease study 2021 across 204 countries and territories. Numbers, age-standardized rates, and average annual percent change of HF attributable to hypertensive heart disease prevalence and years lived with disability were compared by age, sex, and socio-demographic index.
Results: In 1990 and 2021, hypertensive heart disease-related HF affected more than 4.6 million and 13 million individuals globally, demonstrating an age-standardized prevalence rate of 125.4 [95% uncertainty interval (UI), 99.0 to 158.0] and 148.3 per 100,000 (95% UI, 117.3-186.3) and an age-standardized years lived with disability rate of 11.2 (95% UI, 7.2-15.7) and 13.2 (95% UI, 8.4-19.1) per 100,000, respectively. Notably, from 1990 to 2021, the global age-standardized prevalence and years lived with disability rates increased consistently, with an average annual percent change of 0.53 (95% CI, 0.52-0.54) and 0.54 (95% CI, 0.53-0.55), respectively.
Conclusions: The global burden of HF attributable to hypertensive heart disease has risen.
期刊介绍:
The American Journal of Hypertension is a monthly, peer-reviewed journal that provides a forum for scientific inquiry of the highest standards in the field of hypertension and related cardiovascular disease. The journal publishes high-quality original research and review articles on basic sciences, molecular biology, clinical and experimental hypertension, cardiology, epidemiology, pediatric hypertension, endocrinology, neurophysiology, and nephrology.